Heart Hospital of Lafayette is the first in Lafayette to offer an innovative new treatment for patients at risk for stroke due to blockages in the neck arteries known as carotid artery disease. The minimally invasive procedure, called TransCarotid Artery Revascularization or TCAR
, utilizes a new FDA-approved neuroprotection system that temporarily reverses blood flow in the artery during the procedure. Dangerous bits of plaque and blood clots that could dislodge and otherwise travel to the brain and cause a stroke are safely diverted away while a dedicated transcarotid
stent is inserted to open and stabilize the blockage.
Dr. Christopher LaGraize
, a vascular surgeon at Heart Hospital of Lafayette is among the first in the country to gain expertise with the TCAR procedure. “TCAR gives me the excellent neuroprotection I expect from carotid endarterectomy, but the procedure is far less invasive which has real
benefit to the patient. They recover quickly with less pain, and the risks of both minor and major complications are significantly decreased,” explained Dr. LaGraize “It represents the modernization of carotid repair.”
Every year, 15 million people worldwide suffer a stroke, also known as a “brain attack.” Nearly six million die
and another five million are left permanently disabled. Stroke is the second leading cause of disability globally. Carotid artery disease is estimated to be the source of stroke in up to a third of cases and there are 400,000 new diagnoses of carotid artery disease made every year in the United States alone.
“TCAR is an important new option in the fight against stroke,
and is particularly suited for the large portion of patients we see who are at higher risk of complications from carotid endarterectomy due to age, other medical conditions, or anatomic issues. Because of its low stroke risk, we think TCAR has the potential to become the standard of care for all patients,” said Michelle Crain, COO, Heart Hospital of Lafayette.
About Heart Hospital of Lafayette
Heart Hospital of Lafayette owned by Our Lady of Lourdes in partnership with physicians is focused on cardiovascular and heart care with a 24/7 heart emergency center. The facility is consistently ranked in the 90th percentile in patient satisfaction and holds top recognitions from organizations like NCR picker and Women’s Choice Award for patient experience. As a hub for innovative medical procedures like TAVR, Cardiac Mems, Therapeutic Hypothermia treatment and others, Heart Hospital of Lafayette is a top choice for when you need cardiovascular care.
About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
The ENROUTE® Transcarotid Neuroprotection (NPS) and Stent System from Silk Road Medical, Inc. are the first devices designed and FDA-approved specifically for TCAR. The ENROUTE Transcarotid Stent is indicated for use in High Surgical Risk patients and is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS). The ENROUTE Transcarotid NPS is used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from a stroke while delivering and implanting the ENROUTE Transcarotid Stent.
About Silk Road Medical
Silk Road Medical, Inc. is a private company located in Sunnyvale, CA, that develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary transcarotid
therapies. Detailed information can be found at www.silkroadmed.com
ENROUTE is a registered trademark of Silk Road Medical, Inc.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Please refer to package insert for indications, contraindications, warnings, precautions, and instructions for use.